Entia secures £16m Series A funding led by BGF and Parkwalk to expand remote cancer care.
The investment will fund UK commercial rollout and US regulatory approval for the company's remote patient monitoring platform.
Entia develops remote patient monitoring technology and predictive analytics to support individuals undergoing cancer treatment. The company combines at-home blood testing with digital solutions to provide personalised health insights.
Healthtech firm Entia has secured £16m in a Series A funding round led by BGF and Parkwalk. The capital will support the commercial rollout of the company's remote patient monitoring system in the UK alongside preparations for US regulatory approval. Liberty, the company's flagship product, allows patients to track symptoms and vital signs while performing full blood count analyses at home, helping clinicians detect complications early.
From the founder
"Providing more care for people outside of hospital is not only beneficial for patients but is highly advantageous for healthcare providers,"
Toby Basey-Fisher
CEO and Founder at Entia
Investor perspective
"We have been consistently impressed by the commitment and enthusiasm of the Entia team to significantly improve remote monitoring solutions for cancer patients. This combined with their scientific acumen has created a uniquely user-friendly means of monitoring vital health information with the dual power to transform quality of life and drive efficiencies for healthcare providers. We look forward to supporting the business on the next phase of their journey."
Joanna Smart
portfolio lead, BGF
Use of funds
- 01Expand into international markets
- 02Accelerate go-to-market
